Last reviewed · How we verify

Cymbalta — Competitive Intelligence Brief

Cymbalta (duloxetine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin and norepinephrine reuptake inhibitor (SNRI). Area: Metabolic.

marketed Serotonin and norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Cymbalta (duloxetine) — Eli Lilly and Company. Potentiates serotonergic and noradrenergic activity in the CNS through unknown exact mechanisms.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cymbalta TARGET duloxetine Eli Lilly and Company marketed Serotonin and norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake 2004-08-03
Pristiq Desvenlafaxine Succinate Pfizer marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake 2008-01-01
Effexor Venlafaxine Hydrochloride Pfizer marketed Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters 1993-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin and norepinephrine reuptake inhibitor (SNRI) class)

  1. Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cymbalta — Competitive Intelligence Brief. https://druglandscape.com/ci/duloxetine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: